2,4,6-TMPEA-NBOMe

vanc 6 2,4,6-TMPEA-NBOMe.svg skin-invert-image Oral, intranasal Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen None 1335331-68-4 ψ-2C-O-NBOMe; 26O-NBOMe; NBOMe-TMPEA-6; N-(2-Methoxybenzyl)-2,4,6-trimethoxyphenethylamine N-[(2-methoxyphenyl)methyl]-2-(2,4,6-trimethoxyphenyl)ethan-1-amine 19 25 1 4 COc1cc(OC)c(c(c1)OC)CCNCc1ccccc1OC 1S/C19H25NO4/c1-21-15-11-18(23-3)16(19(12-15)24-4)9-10-20-13-14-7-5-6-8-17(14)22-2/h5-8,11-12,20H,9-10,13H2,1-4H3 NTLHTSWPAAMHIC-UHFFFAOYSA-N 2,4,6-TMPEA-NBOMe, also known as ψ-2C-O-NBOMe or 26O-NBOMe as well as N-(2-methoxybenzyl)-2,4,6-trimethoxyphenethylamine, is a psychedelic drug of the phenethylamine, ψ-PEA, and N-benzylphenethylamine (NBOMe) families. 2,4,6-TMPEA-NBOMe AIPSIN https://aipsin.com/newsubstance/1144/ ru 1 January 2026 2,4,6-TMPEA-NBOMe. AIPSIN https://aipsin.com/newsubstance/1276/ ru 1 January 2026 Silva ME, Heim R, Strasser A, Elz S, Dove S Theoretical studies on the interaction of partial agonists with the 5-HT2A receptor Journal of Computer-Aided Molecular Design 25 1 51–66 January 2011 21088982 10.1007/s10822-010-9400-2 Shevyrin V, Kupriyanova O, Lebedev AT, Melkozerov V, Eltsov O, Shafran Y, Morzherin Y, Sadykova R Mass spectrometric properties of N-(2-methoxybenzyl)-2-(2,4,6-trimethoxyphenyl)ethanamine (2,4,6-TMPEA-NBOMe), a new representative of designer drugs of NBOMe series and derivatives thereof Journal of Mass Spectrometry 51 10 969–979 October 2016 27388323 10.1002/jms.3808 2016JMSp...51..969S It is the NBOMe derivative of ψ-2C-O (2,4,6-TMPEA). The drug is said to produce psychedelic effects such as visuals. It has been found to act as a potent serotonin 5-HT2A receptor partial agonist, with an EC50 half-maximal effective concentration of 1.7nM and an Emax maximal efficacy of 49%. Silva M Theoretical study of the interaction of agonists with the 5-HT2A receptor 2009 Ph.D. http://epub.uni-regensburg.de/12119/ Universität Regensburg Table 5.1: Agonistic potency (pEC50) and intrinsic activity (Emax) of 5-HT2AR partial agonistic arylethylamines (indole, methoxybenzene and quinazolinedione derivatives) used in the study. [...] 2,4,6-TMPEA-NBOMe was first described in the scientific literature in 2009. Subsequently, it was encountered as a novel designer drug in Russia in 2015. The drug is a controlled substance in Canada under phenethylamine blanket-ban language.Controlled Drugs and Substances Act Department of Justice Canada https://laws-lois.justice.gc.ca/eng/acts/c-38.8/FullText.html 19 January 2026 See also 25-NB (psychedelics) NBOMe-mescaline (3,4,5-TMPEA-NBOMe) 25O-NBOMe (2,4,5-TMPEA-NBOMe) References External links 26O-NBOMe - Isomer Design Category:5-HT2A agonists Category:Ψ-PEA Category:N-Benzylphenethylamines Category:Designer drugs Category:Methoxyphenethylamines Category:Psychedelic phenethylamines Category:Trimethoxyphenyl compounds